Back to top

MTN-026 was a Phase I study that evaluated the rectal safety of a gel containing 0.05 percent of the antiretroviral drug dapivirine, which was originally developed for vaginal use, as well as the levels of drug detected in blood, rectal fluid and rectal tissue after use. The study, which enrolled 27 HIV-negative cisgender and transgender men and women at sites in Thailand and the U.S., showed the gel was well-tolerated and acceptable to participants, with tissue concentrations suggesting a longer-acting formulation or a higher-dose gel would be required to provide effective protection from HIV transmission through anal sex. These and other results were reported in February 2021 during the virtual HIV R4P conference.  (See also MTN-033.)

Bottoms Are Up at the HIV Research for Prevention Virtual Conference

MTN-026 Backgrounder

MTN-026 Q&A

See Also
MTN-026 Protocol

MTN-026 Study Page

Rectal Microbicides - Fact Sheet